Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,000 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 43,000 F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10 | Direct | 16,900 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900 F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date October 31, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 223,993 |
Reported balance
Holding disclosure · report date 2023-10-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 223,993 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,900 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001770252-26-000003 · wk-form4_1781296109.xml · derivative · entry 2 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 Underlying: Stock Option (Rights to Buy) · 16,900 shares Expires 2036-06-10 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 5,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-26-000003 · wk-form4_1781296109.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,000 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 38,300 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001724521-25-000086 · wk-form4_1749760070.xml · derivative · entry 2 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2035-06-09 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000086 · wk-form4_1749760070.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,300 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001724521-24-000110 · wk-form4_1717798788.xml · derivative · entry 2 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000110 · wk-form4_1717798788.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 7,247 | $15.01 | $108,777.47 |
DisclosureSEC source: 0001770252-23-000009 · wk-form4_1696969151.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,993 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,864 | $15.01 | $73,008.64 |
DisclosureSEC source: 0001770252-23-000009 · wk-form4_1696969151.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,240 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,402 | $15.99 | $70,387.98 |
DisclosureSEC source: 0001770252-23-000007 · wk-form4_1695846455.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,104 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2023. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:11 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001209191-23-038150 · doc4.xml · derivative · entry 2 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:11 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038150 · doc4.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 21:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 6,433 | $23.48 | $151,046.84 |
DisclosureSEC source: 0001770252-23-000004 · wf-form4_168003861168211.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,506 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on November 9, 2022. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,124 | $23.72 | $74,101.28 |
DisclosureSEC source: 0001628280-23-009261 · wf-form4_167994884975705.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,939 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,143 | $23.72 | $50,831.96 |
DisclosureSEC source: 0001628280-23-009261 · wf-form4_167994884975705.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,063 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 20:28 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,419 | $22.91 | $55,419.29 |
DisclosureSEC source: 0001628280-23-009047 · wf-form4_167960328178070.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,206 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 39,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008322 · wf-form4_167899866500395.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,625 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 13,184 | $22.74 | $299,822.62 |
DisclosureSEC source: 0001770252-23-000002 · wf-form4_167788101472427.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,220 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.97, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 23:07 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 853 | $14.51 | $12,377.03 |
DisclosureSEC source: 0001770252-23-000001 · wf-form4_167287361378749.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,404 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on December 30, 2022. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 7,251 | $19.62 | $142,264.62 |
DisclosureSEC source: 0001628280-22-026250 · wf-form4_166552043913445.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,257 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,867 | $19.62 | $95,490.54 |
DisclosureSEC source: 0001628280-22-026250 · wf-form4_166552043913445.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,508 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 20:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,950 | $18.41 | $54,309.50 |
DisclosureSEC source: 0001628280-22-025566 · wf-form4_166431073246152.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,375 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2022. Read SEC document |
| September 25, 2022 Filed Sep 27, 2022 20:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 642 | $18.69 | $11,998.98 |
DisclosureSEC source: 0001628280-22-025566 · wf-form4_166431073246152.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,325 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2022. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,132 | $24.89 | $28,175.48 |
DisclosureSEC source: 0001628280-22-023768 · wf-form4_166154535435807.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,967 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2022. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:25 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,800 | $0.00 Strike: $20.62 | $0.00 |
DisclosureSEC source: 0001209191-22-037414 · doc4.xml · derivative · entry 2 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2032-06-13 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:25 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037414 · doc4.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:02 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,178 | $25.32 | $80,466.96 |
DisclosureSEC source: 0001770252-22-000006 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,099 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:02 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,169 | $25.32 | $54,919.08 |
DisclosureSEC source: 0001770252-22-000006 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,277 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 33,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-22-000004 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,446 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 22:14 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 43,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-22-000002 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,781 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:39 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-21-000019 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,486 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026. F2 · balance_after: Includes 317 shares of Myriad common stock that were omitted from the reporting person's Form 3, which was amended to reflect such shares on November 1, 2021. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:46 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 7,470 | $30.88 | $230,673.60 |
DisclosureSEC source: 0001770252-21-000015 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,169 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:46 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,013 | $30.88 | $154,801.44 |
DisclosureSEC source: 0001770252-21-000015 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,639 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 1,420 | $31.57 | $44,834.51 |
DisclosureSEC source: 0001770252-21-000013 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,652 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 01:13 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,112 | $33.10 | $334,746.64 |
DisclosureSEC source: 0001770252-21-000011 · edgardoc.xml · nonDerivative · entry 3 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,072 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.43 to $33.62, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2021 Filed Sep 28, 2021 01:13 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,426 | $33.31 | $114,120.06 |
DisclosureSEC source: 0001770252-21-000011 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,184 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 25, 2021 Filed Sep 28, 2021 01:13 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,311 | $33.31 | $43,669.41 |
DisclosureSEC source: 0001770252-21-000011 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,610 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:24 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 65,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-21-000009 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,921 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 20:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 945 | $34.50 | $32,602.50 |
DisclosureSEC source: 0001770252-21-000007 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,051 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 01:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,123 | $34.81 | $39,091.63 |
DisclosureSEC source: 0001770252-21-000005 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,996 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 21,700 | $0.00 Strike: $30.02 | $0.00 |
DisclosureSEC source: 0001209191-21-049938 · doc4.xml · derivative · entry 2 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,700 Underlying: Common Stock · 21,700 shares Expires 2031-08-02 F2 · derivative.exercise_date: The option is exercisable in 36 equal monthly installments after August 3, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049938 · doc4.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 F1 · shares: Represents the grant of restricted stock units that vest in three equal annual installments on each of September 15, 2022, September 15, 2023, and September 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 5,890 | $27.01 | $159,085.96 |
DisclosureSEC source: 0001770252-21-000004 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,119 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 759 | $27.01 | $20,499.76 |
DisclosureSEC source: 0001770252-21-000004 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,009 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 29,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-21-000002 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, Myriad Oncology, 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,768 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 12:14 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 44,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001770252-20-000010 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,212 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 591 | $13.04 | $7,706.64 |
DisclosureSEC source: 0001770252-20-000008 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,001 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 26, 2020 Filed Sep 28, 2020 16:59 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,935 | $12.44 | $36,511.40 |
DisclosureSEC source: 0001770252-20-000006 · edgardoc.xml · nonDerivative · entry 4 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,592 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 16:59 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 628 | $12.44 | $7,812.32 |
DisclosureSEC source: 0001770252-20-000006 · edgardoc.xml · nonDerivative · entry 3 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,527 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 16:59 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 13 | $12.44 | $161.72 |
DisclosureSEC source: 0001770252-20-000006 · edgardoc.xml · nonDerivative · entry 2 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,155 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 16:59 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 628 | $12.44 | $7,812.32 |
DisclosureSEC source: 0001770252-20-000006 · edgardoc.xml · nonDerivative · entry 1 Lambert Nicole · CIK 0001770252 · President, MGL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,168 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.